362 related articles for article (PubMed ID: 12620735)
21. Cardiovascular disease costs associated with uncontrolled hypertension.
Flack JM; Casciano R; Casciano J; Doyle J; Arikian S; Tang S; Arocho R
Manag Care Interface; 2002 Nov; 15(11):28-36. PubMed ID: 12449899
[TBL] [Abstract][Full Text] [Related]
22. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
Gaziano TA
Heart; 2008 Feb; 94(2):140-4. PubMed ID: 18195120
[TBL] [Abstract][Full Text] [Related]
23. Reducing population salt intake worldwide: from evidence to implementation.
He FJ; MacGregor GA
Prog Cardiovasc Dis; 2010; 52(5):363-82. PubMed ID: 20226955
[TBL] [Abstract][Full Text] [Related]
24. Design, content and financing of an essential national package of health services.
Bobadilla JL; Cowley P; Musgrove P; Saxenian H
Bull World Health Organ; 1994; 72(4):653-62. PubMed ID: 7923544
[TBL] [Abstract][Full Text] [Related]
25. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
Fodor JG; Whitmore B; Leenen F; Larochelle P
CMAJ; 1999 May; 160(9 Suppl):S29-34. PubMed ID: 10333851
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of interventions to reduce dietary salt intake.
Cobiac LJ; Vos T; Veerman JL
Heart; 2010 Dec; 96(23):1920-5. PubMed ID: 21041840
[TBL] [Abstract][Full Text] [Related]
27. Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease.
Oldridge NB
Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):130-9. PubMed ID: 18391637
[TBL] [Abstract][Full Text] [Related]
28. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
29. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH
Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of cataract surgery: a global and regional analysis.
Baltussen R; Sylla M; Mariotti SP
Bull World Health Organ; 2004 May; 82(5):338-45. PubMed ID: 15298224
[TBL] [Abstract][Full Text] [Related]
32. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
[TBL] [Abstract][Full Text] [Related]
33. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use.
Asaria P; Chisholm D; Mathers C; Ezzati M; Beaglehole R
Lancet; 2007 Dec; 370(9604):2044-53. PubMed ID: 18063027
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations.
Webb M; Fahimi S; Singh GM; Khatibzadeh S; Micha R; Powles J; Mozaffarian D
BMJ; 2017 Jan; 356():i6699. PubMed ID: 28073749
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
Ortegón M; Lim S; Chisholm D; Mendis S
BMJ; 2012 Mar; 344():e607. PubMed ID: 22389337
[TBL] [Abstract][Full Text] [Related]
36. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees.
Greene BL; Miller JD; Brown TM; Harshman RS; Richerson GT; Doyle JJ
J Occup Environ Med; 2009 May; 51(5):542-53. PubMed ID: 19365286
[TBL] [Abstract][Full Text] [Related]
37. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model.
Zomer E; Owen A; Magliano DJ; Liew D; Reid CM
BMJ; 2012 May; 344():e3657. PubMed ID: 22653982
[TBL] [Abstract][Full Text] [Related]
39. Projected effect of dietary salt reductions on future cardiovascular disease.
Bibbins-Domingo K; Chertow GM; Coxson PG; Moran A; Lightwood JM; Pletcher MJ; Goldman L
N Engl J Med; 2010 Feb; 362(7):590-9. PubMed ID: 20089957
[TBL] [Abstract][Full Text] [Related]
40. Global burden of blood-pressure-related disease, 2001.
Lawes CM; Vander Hoorn S; Rodgers A;
Lancet; 2008 May; 371(9623):1513-8. PubMed ID: 18456100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
